MYC-MAX INHIBITORS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH
Provided herein are Myc-Max inhibitory compounds having the structure of Formula I or Formula II and compositions thereof for use in the treatment of cancer. In particular, the Myc- Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer; lymphoma; neuroblastoma; breast cancer; colon cancer; cervical cancer; small-cell lung carcinoma; osteosarcoma; glioblastoma; melanoma; and myeloid leukaemia..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 31. Aug. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
TCHERKASSOV ARTEM [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-08-31, Last update posted on www.tib.eu: 2023-09-21, Last updated: 2023-09-29 |
|---|
| Patentnummer: |
WO2023159303 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA001780166 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA001780166 | ||
| 003 | DE-627 | ||
| 005 | 20240327213500.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA001780166 | ||
| 035 | |a (EPA)WO2023159303 | ||
| 035 | |a (EPA)87764242 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a TCHERKASSOV ARTEM |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MYC-MAX INHIBITORS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-08-31, Last update posted on www.tib.eu: 2023-09-21, Last updated: 2023-09-29 | ||
| 520 | |a Provided herein are Myc-Max inhibitory compounds having the structure of Formula I or Formula II and compositions thereof for use in the treatment of cancer. In particular, the Myc- Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer; lymphoma; neuroblastoma; breast cancer; colon cancer; cervical cancer; small-cell lung carcinoma; osteosarcoma; glioblastoma; melanoma; and myeloid leukaemia. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a C07C: Acyclic or carbocyclic compounds (macromolecular compounds c08;production of organic compounds by electrolysis or electrophoresis c25b0003000000, c25b0007000000) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a RENNIE PAUL |4 aut | |
| 700 | 0 | |a BAN FUQIANG |4 aut | |
| 700 | 0 | |a LEBLANC ERIC |4 aut | |
| 700 | 0 | |a CARABET LAVINIA |4 aut | |
| 700 | 0 | |a LALLOUS NADA |4 aut | |
| 700 | 0 | |a SINGH KRITI |4 aut | |
| 700 | 0 | |a MORIN HELENE |4 aut | |
| 700 | 0 | |a TON ANH-TIEN |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 31. Aug. |
| 773 | 1 | 8 | |g year:2023 |g day:31 |g month:08 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/87764242/publication/WO2023159303A1?q=WO2023159303 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 31 |c 08 | ||